Cara Therapeutics Inc (NAS:CARA)
$ 0.304 0.0159 (5.52%) Market Cap: 16.68 Mil Enterprise Value: -21.94 Mil PE Ratio: 0 PB Ratio: 23.38 GF Score: 33/100

Cara Therapeutics Inc to Discuss KOMFORT Phase 2 Topline Data - Conference Call Transcript

Jun 30, 2022 / 12:30PM GMT
Release Date Price: $9.13 (-4.90%)
Operator

Good morning. My name is Liz, and I will be your conference facilitator. I'd like to welcome everyone to Cara Therapeutics call to discuss the top line results of the KOMFORT Phase II proof-of-concept study in NP. (Operator Instructions)

Please be advised that this call is being recorded. I would now like to introduce Iris Francesconi, Chief Strategy Officer and Head of Investor Relations from Cara Therapeutics. Ms. Francesconi, you may begin the call.

Iris Francesconi
Cara Therapeutics, Inc. - Chief of Corporate Strategy & IR

Thank you, Liz, and good morning, everyone. Earlier today, we issued a press release detailing our top line results for the proof-of-concept study, KOMFORT, in notalgia paresthetica. The press release can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call on the Investors section of the website. Participating in today's call are Chris Posner, Cara's President and Chief Executive Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot